Tirzepatide for type 2 diabetes associated with lower risks for mortality, adverse heart, kidney events
For patients with type 2 diabetes, treatment with tirzepatide (a dual glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist) is associated with lower risks for all-cause mortality and adverse ...
Aug 12, 2024
0
12